Atuka is pleased to launch the inaugural entry in our Discovery Series, focusing on D1 Dopamine Receptor Positive Allosteric Modulators (D1 PAMs) as a promising approach for Parkinson’s disease (PD) research and therapy. In this ongoing series, we will continue to survey other emerging targets and possibilities.
Authored by Dr. Jonathan Brotchie and Dr. Tom Johnston, this review explores the latest research and literature on D1 PAMs, which may engage the dopamine system to address motor and non-motor symptoms with greater selectivity and fewer side effects than traditional treatments.
Why D1 PAMs?
- Novel Mode of Action
D1 PAMs enhance receptor’s affinity for dopamine, or enhances the efficacy of dopamine, rather than activating the receptor directly, potentially reducing tolerance and side effects. - Motor & Cognitive Impact
Evidence suggests these modulators may offer improved motor control while also targeting cognitive deficits—an area of growing emphasis in PD. - Clinical Relevance
Early-phase trials indicate an encouraging safety profile, with several D1 PAMs now under study by leading pharmaceutical developers.
What You’ll Learn
- Mechanisms & Selectivity
Understand how positive allosteric modulation may deliver more physiologically relevant dopamine activity for individuals with PD. - Preclinical to Clinical Evidence
A detailed survey of key findings from rodent and non-human primate studies, plus early-phase human trials highlighting efficacy and safety. - Challenges & Future Directions
Get an overview of ongoing hurdles—such as the potential for species-specific responses and long-term effects—and consideration of how to choose specific translational goal(s) to pursue for the best chance of clinical success. - Key compounds and their profiles
An overview of six D1 PAMs currently under development, including DETQ, DPTQ, UCB0022, Mevidalen, LY3154885 and UCM-1306.
Download the Full Report
Discover the potential of D1 PAMs in reshaping Parkinson’s disease therapy.
Access the full document here to explore the science, data, and expert perspectives behind this emerging treatment avenue.
Related Reading
As world leaders in Parkinson’s research, with a proven track record evaluating over 300 potential therapeutics, Atuka’s scientists bring decades of experience in designing preclinical studies that deliver actionable results.
Explore our recently published insights on Optimizing Preclinical Studies for Parkinson’s Disease Therapeutics to see how Atuka is helping to shape the future of PD research.
Contact Us
For inquiries or to discuss how Atuka can support your Parkinson’s disease research, please reach out or schedule a conversation via our contact page.